Inborn errors in metabolism and 4-boronophenylalanine-fructose-based boron neutron capture therapy.

@article{Laakso2003InbornEI,
  title={Inborn errors in metabolism and 4-boronophenylalanine-fructose-based boron neutron capture therapy.},
  author={J. T. Laakso and I. Ruokonen and Risto Lapatto and Merja Kallio},
  journal={Radiation research},
  year={2003},
  volume={160 5},
  pages={
          606-9
        }
}
Infusions of boronophenylalanine-fructose complex (BPA-F), at doses up to 900 mg/kg of BPA and 860 mg/kg of fructose, have been used to deliver boron to cancer tissue for boron neutron capture therapy (BNCT). In patients with phenylketonuria (PKU), phenylalanine accumulates, which is harmful in the long run. PKU has been an exclusion criterion for BPA-F-mediated BNCT. Fructose is harmful to individuals with hereditary fructose intolerance (HFI) in amounts currently used in BNCT. The harmful… CONTINUE READING

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 37 REFERENCES

Assessment of the results from the phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician’s point of view

A. Z. Diaz
  • J. Neurooncol
  • 2003

Clin - ical implementation of 4 - dihydroxyphenylalanine synthesised by an asymmetric pathway

J. Vähätalo Kulvik, E. Buchar, +6 authors M. Kallio
  • Eur . J . Pharm . Sci .
  • 2003

Sauerwein and A . Zurlo , The EORTC Boron Neutron Capture Therapy ( BNCT ) Group : achievements and future projects

J. Capala Svantesson, K. Markides, J. Pettersson
  • Eur . J . Cancer
  • 2002

achievements and future projects

W. Sauerwein, A. Zurlo, The EORTC Boron Neutron Capture Therapy Group
  • Eur. J. Cancer 38, S31–S34
  • 2002
VIEW 2 EXCERPTS